Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes

Diabetes

Volumn 52, Issue 5, 2003, Pages 1059-1065

  Greenbaum, Carla J ^a   Harrison, Leonard C ^b  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; INSULIN DEPENDENT DIABETES MELLITUS; METHODOLOGY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION;

ADULT; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; QUALITY ASSURANCE, HEALTH CARE; TREATMENT OUTCOME;

EID: 0037407317     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.5.1059     Document Type: Review

References (109)

1. Atkinson MA, Leiter EH: The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604, 1999
2. Bottazzo G, Gleichmann H: Immunology and Diabetes Workshops: report of the First International Workshop on the Standardization of Cytoplasmic Islet Cell Antibodies. Diabetologia 29:125-126, 1986
3. Bonifacio E, Lernmark A, Dawkins RL: Serum exchange and use of dilutions have improved precision measurement of islet cell antibodies. J Immunologic Methods 106:83-88, 1988
4. Boitard C, Bonifacio E, Bottazzo G, Gleichmann H, Molenaar J: Immunology and Diabetes Workshop: report on the Third International (Stage 3) Workshop on the Standardization of Cytoplasmic Islet Cell Antibodies. Diabetologia 31:451-452, 1988
5. Wilkin T, Palmer J, Kurta A, Bonifacio E, Diaz J-L: The Second International Workshop on the Standardization of Insulin Autoantibody (IAA) Measurement. Diabetologia 31:449-450, 1988
6. Bonifacio E, Boitard C, Gleichmann H, Shattock MA, Molenaar JL, Bottazzo GF: Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. Diabetologia 33:731-736, 1990
7. Lernmark A, Molenaar JL, van Beers WA, Yamaguchi Y, Nagatald S, Ludvigsson J, Maclaren NK: The Fourth International Serum Exchange Workshop to Standardize Cytoplasmic Islet Cell Antibodies: The Immunology and Diabetes Workshops and Participating Laboratories. Diabetologia 34:534-535, 1991
8. Greenbaum C, Palmer J, Nagataki S, Yamaguchi Y, Molenaar J, VanBeers W, Maclaren N, Lernmark A: Improved specificity of ICA assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop. Diabetes 41:1570-1574, 1992
9. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H: Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus that those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 74:1040-1044, 1992
10. Greenbaum C, Wilkin T, Palmer J: Fifth International Serum Exchange Workshop for Insulin Autoantibody (IAA) Standardization. Diabetologia 35:798-800, 1992
11. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC: High level of concordance between assays for glutamic acid decarboxylase antibodies: the First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 43:1005-1009, 1994
12. Bingley P: Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Diabetes 45:1720-1728, 1996
13. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS: Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47:1857-1866, 1998
14. Colman PG, Stewart V, Kean J, Koschmann M, Alford F, Ward G, Deam D, Harrison LC: Comparison of two commonly used standard intravenous glucose tolerance tests. Diabetes Care 15:1053-1055, 1992
15. Koschmann M, Alford FP, Ward GM, Walters J, Clolman PG, Harrison LC: Reproducibility of estimating first phase insulin responses to intravenous glucose. Diab Nutr Metab 5:73-79, 1992
16. Bingley PJ, Colman P, Eisenbarth GS, Jackson RA, McCulloch DK, Riley WJ, Gale EA: Standardization of IVGTT to predict IDDM. Diabetes Care 15:1313-1316, 1992
17. McCulloch D, Bingley P, Colman P, Jackson R, Gale E: Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. Diabetes Care 16:911-915, 1993
18. McNair PD, Colman PG, Alford A, Harrison LC: Reproducibility of the first phase insulin response to intravenous glucose is not improved by retrograde cannulation and arterialization or the use of a lower glucose dose. Diabetes Care 18:1168-1173, 1995
19. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI: Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine. Diabetes 34:1306-1308, 1985
20. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S: Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319:599-604, 1988
21. Canadian-European Randomized Trial Group: Cyclosporin-induced remission of IDDM: after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574-1582, 1988
22. Cook JJ, Hudson I, Harrison LC, Dean B, Colman PG, Werther GA, Warne GL, Court JM: Double-blind controlled trial of azathioprine in children with newly diagnosed type 1 diabetes. Diabetes 38:779-783, 1989
23. Mendola G, Casamitjana R, Gomis R: Effect of nicotinamide therapy upon B-cell function in newly diagnosed type I (insulin-dependent) diabetic patients. Diabetologia 32:160-162, 1989
24. Shah S, Malone J, Simpson N: A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320:550-554, 1989
25. Vague P, Picq R, Bernal M, Lassman-Vague V, Vialettes B: Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 32:316-321, 1989
26. Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, O'Brien D: A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33:444-446, 1990
27. Giordano C, Panto F, Amato MP, Sapienza N, Pugliese A, Galluzzo A: Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus. J Autoimmun 3:611-617, 1990
28. Secchi A, Pastore MR, Sergi A, Pontiroli AE, Pozza G: Prednisone administration in recent onset type 1 diabetes. J Autoimmun 3:593-600, 1990
29. Skyler JS, Rabinovitch A: Cyclosporine in recent onset type 1 diabetes mellitus: effects on islet beta cell function: Miami Cyclosporine Diabetes Study Group. J Diabetes Complications 6:77-88, 1992
30. Goday A, Pujol-Borrell R, Fernandez J, Casamitjana R, Rios M, Vilardell E, Gomis R: Effects of a short prednisone regime at clinical onset of type 1 diabetes. Diabetes Res Clin Pract 20:39-46, 1993
31. Muir A, Schatz D, Maclaren N: Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev 9:279-287, 1993
32. Skyler JS, Lorenz TJ, Schwartz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Saria EA, Byers V: Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type 1 diabetes mellitus: a preliminary investigation: the CD5 Diabetes Project Team. J Diabetes Complications 7:224-232, 1993
33. Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, Boccuni ML, Fava D, Gragnoli C, Andreani D: Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 38:848-852, 1995
34. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA: Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 45:1427-1430, 1996
35. Kohnert KD, Hehmke B, Keilacker H, Ziegler M, Emmrich F, Laube F, Michaelis D: Antibody response to islet antigens in anti-CD4/prednisolone immune intervention of type 1 diabetes. Int J Clin Lab Res 26:55-59, 1996
36. Linn T, Ortac K, Laube H, Federlin K: Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism 45:1508-1513, 1996
37. Schnell O, Eisfelder B, Standl E, Ziegler AG: High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 46:1607-1611, 1997
38. Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, Carel JC, Ludvigsson J, Boitard C, Bougneres PF: Low dose linomide in type 1 juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 41:1040-1046, 1998
39. Elliott JF, Marlin KL, Couch RM: Effect of Bacillus Calmette-Guerin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 21:1691-1693, 1998
40. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP: Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes: a randomized clinical study. Diabetes Care 22:1703-1707, 1999
41. Buckingham BA, Sandborg CI: A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 96:86-90, 2000
42. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Marechaud R, Bougneres P, Charbonnel B, Sai P: Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial: Diabete Insuline Orale group. Lancet 356:545-549, 2000
43. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, Manca Bitti ML, Matteoli MC, Marietti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G: No effect of oral insulin on residual β-cell function in recent-onset type 1 diabetes (the IMDIAB VII): IMDIAB Group. Diabetologia 43:1000-1004, 2000
44. Vidal J, Fernandez-Balsells M, Sesmilo G, Aguilera E, Casamitjana R, Gomis R, Conget I: Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 23:360-364, 2000
45. Rjasanowski I, Michaelis D, Besch W, Keilacker H, Ziegler B, Hildmann W: Glucose tolerance behaviour before the onset of type I (insulin-dependent) diabetes in young people as a predictor of the further course of the disease: a retrospective analysis of 33 cases. Diabetes Res Clin Pract 11:107-115, 1991
46. Greenbaum CJ, Cuthbertson D, Krischer JP, the DPT-1 Study Group: Type 1 diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 50:470-476, 2001
47. Caillat-Zucman S, Garchon HJ, Timsit J, Assan R, Boitard C, Djilali-Saiah I, Bougneres P, Bach JF: Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest 90:2242-2250, 1992
48. Tait BD, Harrison LC, Drummond BP, Stewart V, Varney MD, Honeyman MC: HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum Immunol 42:116-122, 1995
49. Honeyman MC, Harrison LC, Drummond B, Colman PG, Tait BD: Analysis of families at risk for insulin-dependent diabetes reveals that HLA antigens influence progression to preclinical disease. Mol Med 1:576-582, 1995
50. Madsbad S, Faber O, Binder C, McNair P, Christiansen C, Transbol I: Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 27 (Suppl. 1):262-264, 1978
51. Bonora E, Coscelli C, Butturini U: Residual B-cell function in type 1 (insulin-dependent) diabetes mellitus: its relation to clinical and metabolic features. Acta Diabetol Lat 21:375-383, 1984
52. Sochett EB, Daneman D, Clarson C, Ehrlich RM: Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 30:453-459, 1987
53. Diabetes Control and Complications Trial Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 65:30-36, 1987
54. Schiffrin A, Suissa S, Poussier P, Guttmann R, Weitzner G: Prospective study of predictors of beta-cell survival in type 1 diabetes. Diabetes 37:920-925, 1988
55. Ludvigsson J, Binder C, Mandrup-Poulsen T: Insulin autoantibodies are associated with islet cell antibodies; their relation to insulin antibodies and β-cell function in diabetic children. Diabetologia 31:647-651, 1988
56. Peig M, Gomis R, Ercilla G, Casamitjana R, Bottazzo GF, Pujol-Borrell R: Correlation between residual beta-cell function and islet cell antibodies in newly diagnosed type I diabetes: follow-up study. Diabetes 38:1396-1401, 1989
57. Couper JJ, Hudson I, Werther GA, Warne GL, Court JM, Harrison LC: Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes. Diabetes Res Clin Pract 11:9-16, 1991
58. Montanya E, Fernandez-Castaner M, Rosel P, Gomez J, Soler J: Age, sex and ICA influence on beta-cell secretion during the first year after the diagnosis of type 1 diabetes mellitus. Diabet Metab 17:460-468, 1991
59. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D: Factors predicting course of beta-cell function in IDDM. Diabetes Care 15:997-1001, 1992
60. Hramiak IM, Dupre J, Finegood DT: Deternunants of clinical remission in recent-onset IDDM. Diabetes Care 16:125-132, 1993
61. Yokota I, Shirakawa N, Shima K, Matsuda J, Naito E, Ito M, Kuroda Y: Relationship between GAD antibody and residual beta-cell function in children after overt onset of IDDM. Diabetes Care 19:74-75, 1996
62. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E: Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus. Diabet Med 15:844-850, 1998
63. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J, Akerblom HK, Knip M: Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes: the Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 84:1534-1539, 1999
64. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J: Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619-4623, 2000
65. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y: A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies: Osaka IDDM Study Group. N Engl J Med 342:301-307, 2000
66. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y: A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence. Ann Med 32:539-543, 2000
67. Hoogwerf BJ, Rich SS, Barbosa JJ: Meal-stimulated C-peptide and insulin antibodies in type I diabetic subjects and their nondiabetic siblings characterized by HLA-DR antigens. Diabetes 34:440-445, 1985
68. Bingley P: Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set: Islet Cell Antibody Register Users Study. Diabetes 45:1720-1728, 1996
69. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS: Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 45:926-933, 1996
70. Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G: Combinations of beta-cell-specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33:115-120, 2001
71. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA: Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11:299-303, 1994
72. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I: Crucial points at diagnosis: type 2 diabetes or slow type 1 diabetes. Diabetes Care 22 (Suppl. 2):59-64, 1999
73. Carlsson A, Sundkvist G, Groop L, Tuomi T: Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85:76-80, 2000
74. Hathout EH, Thomas W, El-Shahawy M, Nahab F, Mace JW: Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 107:E102, 2001
75. Ludvigsson J, Heding LG: Beta-cell function in children with diabetes. Diabetes 27 (Suppl. 1):230-234, 1978
76. Faber O: Beta-cell function and diabetic control in insulin dependent diabetes mellitus. Acta Endocrinol Suppl (Copenh) 272:73-77, 1985
77. Faber OK, Binder C: C-peptide: an index of insulin secretion. Diabetes Metab Rev 2:331-345, 1986
78. Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med 128:517-523, 1998
79. Shimada A, Charlton B, Taylor-Edwards C, Fathman CG: Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 45:1063-1067, 1996
80. Keller R, Eisenbarth GS: Immunopathogenesis of type 1 diabetes mellitus. In Immunotherapy of Diabetes and Selected Autoimmune Diseases. Eisenbarth GS, Ed. Boca Raton, FL, CRC Press, 1989, p. 2-15
81. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45:622-626, 1996
82. Montanya E, Fernandez-Castaner M, Soler J: Improved metabolic control preserved beta-cell function two years after diagnosis of insulin-dependent diabetes mellitus. Diabetes Metab 23:314-319, 1997
83. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
84. Canadian-European Randomized Control Trial Group: cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574-1582, 1988
85. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du RH, Rodier M, Sirmai J, Lallemand A: Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 2:119-124, 1986
86. Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti-R FE, Signore A, Cavallo MG, Andreani D, Lucentini L, et al.: Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1): The IMDIAB Study Group. Diabet Med 11:98-104, 1994
87. Mirel RD, Ginsberg-Fellner F, Horwitz DL, Rayfield EJ: C-peptide reserve in insulin-dependent diabetes: comparative responses to glucose, glucagon and tolbutamide. Diabetologia 19:183-188, 1980
88. Menchini M, Meschi F, Lambiase R, Puzzovio M, Del Guercio MJ, Chiumello G: C-peptide response to arginine stimulation in diabetic children. J Pediatr 96:362-366, 1980
89. Scheen AJ, Castillo MJ, Lefebvre PJ: Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 22:397-406, 1996
90. Rakotoambinina B, Timsit J, Deschamps I, Laborde K, Gautier D, Jos J, Boitard C, Robert JJ: Insulin responses to intravenous glucose, intravenous arginine and a hyperglycaemic clamp in ICA-positive subjects with different degrees of glucose tolerance. Diabetes Metab 23:43-50, 1997
91. Sjoberg S, Gunnarsson R, Ostman J: Residual C-peptide production in type I diabetes mellitus: a comparison of different methods of assessment and influence on glucose control. Acta Med Scand 214:231-237, 1983
92. Heinze E, Beischer W, Keller L, Winkler G, Teller WM, Pfeiffer EF: C-peptide secretion during the remission phase of juvenile diabetes. Diabetes 27:670-676, 1978
93. Skyler JS, Rabinovitch A: Cyclosporine in recent onset type I diabetes mellitus: effects on islet beta cell function: Miami Cyclosporine Diabetes Study Group. J Diabetes Complications 2:77-88, 1992
94. Ronnemaa T: Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Lab Invest 46:345-349, 1986
95. Pasquali R, Buratti P, Biso P, Patrono D, Capelli M, Pasqui F, Melchionda N: Estimation of B-cell function by the urinary excretion rate of C-peptide in diabetic patients: comparison with C-peptide response to glucagon and to a mixed meal. Diabetes Metab 13:44-51, 1987
96. Daneman D, Clarson C: Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 10:484-487, 1987
97. Arnold-Larsen S, Madsbad S, Kuhl C: Reproducibility of the glucagon test. Diabet Med 4:299-303, 1987
98. Ludvigsson J: Methodological aspects on C-peptide measurements. Acta Med Scand Suppl 671:53-59, 1983
99. Madsbad S, Sauerbrey N, Moller-Jensen B, Krarup T, Kuhl C: Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Acta Med Scand 222:71-74, 1987
100. Gjessing HJ, Reinholdt B, Faber OK, Pedersen O: The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 124:556-562, 1991
101. Mandrup-Poulsen T, Molvig J, Andersen HU, Helqvist S, Spinas GA, Munck M: Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients: the Canadian-European Randomized Control Trial Group. Diabetes 39:204-210, 1990
102. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R: Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 303:302-307, 1980
103. Kahaly G, Pitz S, Muller-Forell W, Hommel G: Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 106:197-202, 1996
104. Couper JJ, Harrison LC, Aldis JE, Colman PG, Honeyman MC, Ferrante A: IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Human Immunol 59:493-499, 1998
105. Bonifacio E, Scirpoli M, Kredel K, Fuchtenbusch M, Ziegler AG: Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 163:525-532, 1999
106. Harrison LC, Chu XS, DeAizpurua HJ, Graham M, Honeyman MC, Colman PG: Islet-reactive T cells are a marker of pre-clinical insulin-dependent diabetes. J Clin Invest 89:1161-1165, 1992
107. Durinovic-Bellò I, Hummel M, Ziegler A: Cellular immune response to diverse islet cell antigens in IDDM. Diabetes 45:795-800, 1996
108. Honeyman MC, Brusic V, Stone N, Harrison LC: Neural network-based prediction of candidate T-cell epitopes. Nature Biotech 16:966-970, 1998
109. Roep BO, Atkinson MA, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA: Autoreactive T cell responses in insulin-dependent (type 1) diabetes mellitus: report of the First International Workshop for Standardization of T cell Assays. J Autoimmun 13:267-282, 1999